Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanton R Mehr

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
American Health & Drug Benefits|December 25, 2015
The Latest Innovations in the Drug Pipeline for Multiple SclerosisLea Radick, Stanton R Mehr
The American Journal of Managed Care|January 26, 2015
A patient's opinion of unmet needManny Hernandez, Stanton R Mehr
The American Journal of Managed Care|June 4, 2013
Searching for clinical and economic value in pancreatic cancerMarj P Zimmerman, Stanton R Mehr
Pharmaceutical Medicine|January 15, 2020
Biosimilars in the USA: Will New Efforts to Spur Approvals and Access Spur Uptake and Cost Savings?Stanton R Mehr, Richard A Brook
American Health & Drug Benefits|December 25, 2015
Reviewing the Unmet Needs of Patients with Multiple SclerosisStanton R Mehr, Marj P Zimmerman
The American Journal of Managed Care|January 26, 2015
What is the place of new SGLT-2 inhibitors in therapy and on the formulary?Stanton R Mehr, Marj P Zimmerman
The American Journal of Managed Care|January 11, 2013
Breast cancer: will treatment costs outpace effectiveness?Marj P Zimmerman, Stanton R Mehr
The American Journal of Managed Care|May 31, 2012
Myeloproliferative disorders and myelofibrosisMarjorie P Zimmerman, Stanton R Mehr
The American Journal of Managed Care|January 26, 2015
Robotic-assisted surgery: a question of valueStanton R Mehr, Marj P Zimmerman
Journal of Medical Economics|August 11, 2017
Factors influencing the economics of biosimilars in the USStanton R Mehr, Richard A Brook
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
American Health & Drug Benefits|December 25, 2015
The Latest Innovations in the Drug Pipeline for Multiple SclerosisLea Radick, Stanton R Mehr
The American Journal of Managed Care|January 26, 2015
A patient's opinion of unmet needManny Hernandez, Stanton R Mehr
The American Journal of Managed Care|June 4, 2013
Searching for clinical and economic value in pancreatic cancerMarj P Zimmerman, Stanton R Mehr
Pharmaceutical Medicine|January 15, 2020
Biosimilars in the USA: Will New Efforts to Spur Approvals and Access Spur Uptake and Cost Savings?Stanton R Mehr, Richard A Brook
American Health & Drug Benefits|December 25, 2015
Reviewing the Unmet Needs of Patients with Multiple SclerosisStanton R Mehr, Marj P Zimmerman
The American Journal of Managed Care|January 26, 2015
What is the place of new SGLT-2 inhibitors in therapy and on the formulary?Stanton R Mehr, Marj P Zimmerman
The American Journal of Managed Care|January 11, 2013
Breast cancer: will treatment costs outpace effectiveness?Marj P Zimmerman, Stanton R Mehr
The American Journal of Managed Care|May 31, 2012
Myeloproliferative disorders and myelofibrosisMarjorie P Zimmerman, Stanton R Mehr
The American Journal of Managed Care|January 26, 2015
Robotic-assisted surgery: a question of valueStanton R Mehr, Marj P Zimmerman
Journal of Medical Economics|August 11, 2017
Factors influencing the economics of biosimilars in the USStanton R Mehr, Richard A Brook
Pageof 4